Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR). (1st December 2017)

• Record Type: Journal Article
• Authors: Blauvelt, A.; Ferris, L.K.; Yamauchi, P.S.; Qureshi, A.; Leonardi, C.L.; Farahi, K.; Fakharzadeh, S.; Hsu, M.‐C.; Li, S.; Chevrier, M.; Smith, K.; Goyal, K.; Chen, Y.; Muñoz‐Elías, E.J.; Callis Duffin, K.
• Is Part Of: British journal of dermatology. Volume 177:Number 6(2017)
• Page Start: 1552
• Page End: 1561
• Publication Date: 2017-12-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.15722
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Background Phase III studies showed that some patients maintained response for ≥ 6 months following ustekinumab discontinuation. Objectives To assess clinical responses with extended ustekinumab maintenance dosing intervals. Methods Adults with moderate‐to‐severe plaque psoriasis received ustekinumab at weeks 0, 4 and 16 during open‐label treatment. Patients achieving a week‐28 Physician's Global Assessment (PGA) score of cleared/minimal (PGA = 0/1) were randomized 1 : 4 to group 1 [approved every 12 weeks (q12 wk) maintenance] or group 2 (q12–24 wk; response‐based dosing determined by time to loss of PGA = 0/1). Key end points included the number of visits with PGA = 0/1 (primary end point) and ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) between weeks 88 and 112, and PGA/PASI responses between weeks 28 and 112. Results Overall, 378 patients achieved PGA = 0/1 at week 28 and were randomized to group 1 ( n = 76) or group 2 ( n = 302). Patients in group 1 had numerically greater mean numbers of visits with PGA = 0/1 than group 2 and also with PASI 75 from week 88 to 112. A higher proportion of patients in group 1 (55%) than group 2 (39%) had PGA = 0/1 at all seven visits from week 88 to 112. Maintenance of response was observed with dose‐interval extension beyond q12 wk in a subset of patients. Extending the dosing interval did not affect antibody development or safety. Conclusions Efficacy was better maintained among week‐28 PGA responders randomized to continue q12 wk ustekinumab vs. extending maintenance dosing based on clinical response, although some patients maintained high levels of efficacy with up to q24 wk dosing.